Schrödinger, Inc.

NasdaqGS:SDGR Stock Report

Market Cap: US$1.8b

Schrödinger Valuation

Is SDGR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SDGR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$5.71
Fair Value
345.6% overvalued intrinsic discount
11
Number of Analysts

Below Fair Value: SDGR ($25.43) is trading above our estimate of fair value ($5.71)

Significantly Below Fair Value: SDGR is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SDGR?

Key metric: As SDGR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SDGR. This is calculated by dividing SDGR's market cap by their current revenue.
What is SDGR's PS Ratio?
PS Ratio9.6x
SalesUS$193.35m
Market CapUS$1.82b

Price to Sales Ratio vs Peers

How does SDGR's PS Ratio compare to its peers?

The above table shows the PS ratio for SDGR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.3x
TDOC Teladoc Health
0.7x0.9%US$1.8b
CERT Certara
6x9.0%US$2.2b
PHR Phreesia
4.2x11.0%US$1.7b
GDRX GoodRx Holdings
2.4x5.9%US$1.9b
SDGR Schrödinger
9.6x19.3%US$1.8b

Price-To-Sales vs Peers: SDGR is expensive based on its Price-To-Sales Ratio (9.6x) compared to the peer average (3.3x).

Price to Sales Ratio vs Industry

How does SDGR's PS Ratio compare vs other companies in the US Healthcare Services Industry?

13 CompaniesPrice / SalesEstimated GrowthMarket Cap
EVH Evolent Health
0.5x7.0%US$1.20b
MPLN MultiPlan
0.3x1.9%US$267.15m
CCLD CareCloud
0.5x15.6%US$58.36m
HCTI Healthcare Triangle
0.3xn/aUS$4.52m
SDGR 9.6xIndustry Avg. 2.4xNo. of Companies13PS02.44.87.29.612+
13 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SDGR is expensive based on its Price-To-Sales Ratio (9.6x) compared to the US Healthcare Services industry average (2.4x).

Price to Sales Ratio vs Fair Ratio

What is SDGR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SDGR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.6x
Fair PS Ratio4.2x

Price-To-Sales vs Fair Ratio: SDGR is expensive based on its Price-To-Sales Ratio (9.6x) compared to the estimated Fair Price-To-Sales Ratio (4.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SDGR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$25.43
US$32.18
+26.6%
20.4%US$50.00US$26.00n/a11
Jan ’26US$19.29
US$32.00
+65.9%
21.1%US$50.00US$25.00n/a11
Dec ’25US$22.57
US$32.00
+41.8%
21.1%US$50.00US$25.00n/a11
Nov ’25US$17.99
US$31.45
+74.8%
22.0%US$50.00US$25.00n/a11
Oct ’25US$17.80
US$33.27
+86.9%
20.9%US$50.00US$25.00n/a11
Sep ’25US$21.03
US$33.27
+58.2%
20.9%US$50.00US$25.00n/a11
Aug ’25US$22.60
US$34.27
+51.6%
22.2%US$50.00US$25.00n/a11
Jul ’25US$18.76
US$36.50
+94.6%
19.5%US$50.00US$25.00n/a10
Jun ’25US$21.52
US$36.50
+69.6%
19.5%US$50.00US$25.00n/a10
May ’25US$25.26
US$37.70
+49.2%
17.2%US$50.00US$26.00n/a10
Apr ’25US$26.33
US$37.70
+43.2%
17.2%US$50.00US$26.00n/a10
Mar ’25US$26.81
US$37.70
+40.6%
17.2%US$50.00US$26.00n/a10
Feb ’25US$26.63
US$42.20
+58.5%
20.3%US$60.00US$29.00n/a10
Jan ’25US$35.80
US$44.22
+23.5%
19.3%US$60.00US$29.00US$19.299
Dec ’24US$32.49
US$48.22
+48.4%
29.8%US$80.00US$29.00US$22.579
Nov ’24US$21.82
US$53.44
+145.0%
24.8%US$80.00US$31.00US$17.999
Oct ’24US$28.27
US$56.44
+99.7%
22.8%US$80.00US$31.00US$17.809
Sep ’24US$36.71
US$56.44
+53.8%
22.8%US$80.00US$31.00US$21.039
Aug ’24US$52.33
US$58.56
+11.9%
28.6%US$86.00US$23.00US$22.609
Jul ’24US$49.92
US$55.56
+11.3%
33.9%US$86.00US$23.00US$18.769
Jun ’24US$35.09
US$51.78
+47.6%
38.5%US$86.00US$23.00US$21.529
May ’24US$30.88
US$51.25
+66.0%
40.4%US$86.00US$24.00US$25.268
Apr ’24US$26.33
US$51.38
+95.1%
40.0%US$86.00US$25.00US$26.338
Mar ’24US$24.60
US$55.33
+124.9%
41.2%US$89.00US$25.00US$26.819
Feb ’24US$25.14
US$55.44
+120.5%
42.2%US$87.00US$23.00US$26.639
Jan ’24US$18.69
US$55.67
+197.8%
40.8%US$86.00US$23.00US$35.809
Analyst Price Target
Consensus Narrative from 11 Analysts
US$32.18
Fair Value
21.0% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 22:44
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Schrödinger, Inc. is covered by 18 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gaurav GoparajuBerenberg
Clarence PowellBMO Capital Markets Equity Research
Evan SeigermanBMO Capital Markets Equity Research